Navigation Links
Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache'
Date:4/7/2011

MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the publication of results from the Phase 3 FREEDOM-301 study of  LEVADEX™ orally inhaled migraine drug in the peer-reviewed journal 'Headache.' The manuscript, titled MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine, has been posted online and will appear in the April edition, Volume 51, Issue 4 of Headache: The Journal of Head and Face Pain. LEVADEX is an investigational acute therapy for migraine that has completed Phase 3 clinical development.

"There is general dissatisfaction with existing acute treatment options for migraine because of slow onset of action, inadequate pain relief, and high recurrence rates. Based on the results from the FREEDOM-301 study, LEVADEX has the potential to address many of the unmet needs of migraine sufferers," said Sheena Aurora, M.D., a FREEDOM-301 clinical study investigator, director of the Swedish Headache Center and assistant professor of neurology at the University Of Washington School of Medicine. 

In the FREEDOM-301 study, the efficacy assessment focused on the four major symptoms of migraine at the standard two hour time point for acute migraine studies. All four co-primary endpoints for LEVADEX were met at two hours:

  • Pain relief was observed in 59% of patients in the LEVADEX treatment group compared with 35% in the placebo group (p<0.0001)
  • Phonophobia free was observed in 53% of patients in the LEVADEX treatment group compared with 34% for the placebo group (p<0.0001)
  • Photophobia free was observed in 47% of patients in the LEVADEX treatment group compared with 27% for the placebo group (p<0.0001)
  • Nausea free was observed in 67% of  patients in the LEVADEX treatment group compared with 59% for the placeb
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
    2. MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
    3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
    10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
    (Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
    (Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
    Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
    ... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
    ... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
    Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
    (Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
    (Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
    (Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
    (Date:11/27/2014)... 2014 "The uglier, the better," says Dr. ... is full of laughter as we enjoy the ugly sweater ... a sweater from scratch. " It was a sight to ... that weren't ridiculous enough, the Christmas balls were faces of ... those interested in participating this year, it's simple to get ...
    (Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
    Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
    ... to a hundred years ago are being used in the ... the first time old bones have been used in this ... combination of latest computer modelling techniques developed at the University ... of Bristol. With Engineering and Physical Sciences Research Council ...
    ... core professional obligation and lying, even for a patient, ... Jr., MD, FACP, president of the American College of ... internal medicine physician and medical student members today. ... "sick notes" issued without a medical evaluation to some ...
    ... HealthDay Reporter , MONDAY, Feb. 28 (HealthDay News) ... in which inflammation of the lining of the nose and ... the most severe cases, patients develop nasal polyps that can ... to begin with a steroid nasal spray and then move ...
    ... , MONDAY, Feb. 28 (HealthDay News) -- Few things send ... rising temperature. But, a new report from the American ... reminding parents that a fever is usually just the body,s ... actually prolong an illness. The AAP recommends that, in ...
    ... , MONDAY, Feb. 28 (HealthDay News) -- Heart ... positive outlook, researchers are reporting. More than 2,800 heart ... their belief in their ability to recover from the illness ... 1,637 of the patients had died. Of those deaths, 885 ...
    ... MONDAY, Feb. 28 (HealthDay News) -- The stress of ... and gain weight, researchers report. The Georgia Health ... 60 first-time mothers who were asked about their levels ... a low amount of physical activity, was most influenced ...
    Cached Medicine News:Health News:Learning from old bones to treat modern back pain 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 3Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Stress May Help Spur Weight Gain in New Moms, Study Finds 2
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Medicine Products: